| FRIDAY MARCH 24, 2023 | HALL A | |
| 07:30–08:30 | Iveric Bio Pre-Congress Industry Sponsored Breakfast Symposium:Are You Ready for the Future? Treating Geographic Atrophy with Complement Modulation-Based Therapies (Light breakfast will be served from 07:00-07:30 at the entrance of the hall) |
| Faculty: | Peter K. Kaiser, USA, Baruch D. Kuppermann, USA, Anat Loewenstein, Israel |
| 07:30 | Introduction-pre test |
| 07:35 | Prevalence, Unmet Need, Impact on Quality of Life |
| 07:40 | Imaging Modalities for Assessing Atrophy |
| 07:50 | The atrophy is in the details |
| 08:00 | A discovery of lesions |
| 08:10 | A new era of GA treatments – targeting complement system modulation |
| 08:20 | Patient education and setting expectations |
| 08:25 | Closing remarks – post-test |
 | |
| 12:15–13:15 | Roche Industry Sponsored Luncheon Symposium: Advancing the management of nAMD via Ang-2/VEGF-A dual inhibition (Lunch boxes served 12:00–12:15) |
| Chair: | Ângela Carneiro, Portugal |
| 12:15 | Welcome and opening remarks Ângela Carneiro, Portugal |
| 12:20 | Evidence for Ang-2/VEGF-A inhibition in nAMD: Preclinical and Phase 3 data Rufino Silva, Portugal |
| 12:35 | Real-world clincial case discussions James Talks, UK David Almeida, USA Audience Q&A with the panel |
| 13:10 | Closing remarks Ângela Carneiro, Portugal |
| With the hybrid link you can join the Roche symposia from the comfort of your clinic / office/ living room and follow the real world case studies that will be shared by the expert panel. | |
| |
| 16:15–17:15 | Roche Industry Sponsored Symposium: Advancing the management of DME via Ang-2/VEGF-A dual inhibition |
| Chair: | João Figueira, Portugal |
| 16:15 | Welcome and opening remarks João Figueira, Portugal |
| 16:20 | Evidence for Ang-2/VEGF-A inhibition in DME: Preclinical and Phase 3 data Sara Vaz-Pereira, Portugal |
| 16:35 | Real-world clinical case discussions Sobha Sivaprasad, UK David Almeida, USA Audience Q&A with the panel |
| 17:10 | Closing remarks João Figueira, Portugal |
| With the hybrid link you can join the Roche symposia from the comfort of your clinic / office/ living room and follow the real world case studies that will be shared by the expert panel. | |
| SATURDAY MARCH 25, 2023 | HALL A | |
 | |
| 07:30-08:30 | Ocular Therapeutix Industry Sponsored Symposium:Sustained-Release TKI Therapies to Address Retinal Vascular Diseases (Light breakfast will be served from 07:00-07:30 at the entrance of the hall) |
| Chair: | Peter Kaiser, USA |
| 07:30 | Welcome and Opening Remarks Peter Kaiser, USA |
| 07:35 | The current standard of care for nAMD is ready for disruption: Introduction to tyrosine kinase inhibitors (TKIs) Paolo Lanzetta, Italy |
| 07:45 | Emerging TKI therapies in clinical development to treat nAMD Anat Loewenstein, Israel |
| 07:55 | OTX-TKI: Clinical trial results Peter Kaiser, USA |
| 08:10 | Discussion: Looking into the future – The paradigm shift for retinal vascular diseases Audience Q&A with Panel |
| 08:25 | Closing Remarks Peter Kaiser, USA |
 | |
| 12:15–13:15 | AbbVie Industry Sponsored Luncheon Symposium for Healthcare Professionals Only: Controversies in the management of DME & RVO (Lunch boxes served 12:00 -12:15) |
| Chair: | Anat Loewenstein, Israel |
| 12:15–12:20 | Chair's welcome and introduction Anat Loewenstein, Israel |
| 12:20–12:37 12:20 12:25 12:30 | Aiming for early disease control can impact long term outcomes For: Maria Vittoria Cicinelli, Italy Against: Matias Iglicki, Argentina Discussion |
| 12:37–12:54 12:37 12:42 12:47 | Steroids can be used in suitable patients as first-line treatment For: Peter Addison, UK Against: Faruque Ghanchi, UK Discussion |
| 12:54–13:11 12:54 12:59 13:04 | Artificial Intelligence is changing DME & RVO management today For: Bianca Gerendas, Austria Against: Marco Lupidi, Italy Discussion |
| 13:11–13:15 | Close Anat Loewenstein, Israel |
| All Healthcare Professionals are invited to participate at the using the hybrid link. | |
| Promotional meeting organised and funded by AbbVie. AbbVie Products will be discussed in this meeting. ALL-ABBV-230101 | March 2023 | |
 | |
| 13:30–14:30 | Bayer Sponsored Symposium Have we maximised outcomes for our patients, or can we go further with disease control? (Dessert boxes served 13:15 -13:30) |
| Co-chairs: | Ângela Carneiro, Portugal Anat Loewenstein, Israel |
| 13:30 | Welcome and introductions Ângela Carneiro, Portugal |
| 13:35 | Have we maximised outcomes for our patients? Marion Munk, Switzerland |
| 13:45 | Will targeting new pathways lead to improvements in efficacy outcomes? Michael Stewart, USA |
| 13:55 | Is aflibercept 8mg a game changer? Anat Loewenstein, Israel |
| 14:10 | Panel Discussion All |
| 14:25 | Summary of key learnings Ângela Carneiro, Portugal |
